全文获取类型
收费全文 | 247篇 |
免费 | 62篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 1篇 |
基础医学 | 2篇 |
临床医学 | 36篇 |
内科学 | 154篇 |
神经病学 | 7篇 |
特种医学 | 5篇 |
外科学 | 7篇 |
综合类 | 21篇 |
预防医学 | 4篇 |
药学 | 71篇 |
中国医学 | 2篇 |
肿瘤学 | 2篇 |
出版年
2024年 | 5篇 |
2023年 | 15篇 |
2022年 | 13篇 |
2021年 | 34篇 |
2020年 | 27篇 |
2019年 | 38篇 |
2018年 | 24篇 |
2017年 | 36篇 |
2016年 | 31篇 |
2015年 | 12篇 |
2014年 | 7篇 |
2013年 | 31篇 |
2012年 | 14篇 |
2011年 | 14篇 |
2010年 | 4篇 |
2009年 | 4篇 |
2008年 | 3篇 |
2006年 | 1篇 |
排序方式: 共有313条查询结果,搜索用时 15 毫秒
311.
312.
Joana Costa d'Avila Aluana Santana Carlos Raimundo Lima Vieira Carla Vergueiro Aline Teixeira Lima Isaias dos Santos Silva Vivian Carvalho de Figueiredo Paulo Henrique Petrone Chateaubriand Adalgiza Mafra Moreno Hugo Caire de Castro Faria Neto Vanessa Estato Rodrigo Azeredo Siqueira 《Microcirculation (New York, N.Y. : 1994)》2023,30(7):e12825
Objectives
This study aimed to evaluate the effects of the antidiabetics liraglutide, a GLP-1 analog, and empagliflozin, an SGLT-2 inhibitor, on the brain microcirculation of diabetic rats.Methods
Type 2 diabetes mellitus (DM) was experimentally induced in male Wistar rats by combining a high-fat diet and a low dose of streptozotocin (35 mg/kg). Liraglutide (100 μg/kg s.c.) and empagliflozin (10 mg/kg, oral) were administered for 5 weeks. Body weight was monitored periodically. Oral glucose tolerance, fasting glycemia, and blood triglycerides were evaluated after the treatments. Endothelial–leukocyte interactions in the brain microcirculation and structural capillary density were assessed.Results
DM rats presented metabolic and cerebrovascular alterations. Liraglutide treatment decreased body weight and blood triglycerides of DM rats. Empagliflozin treatment improved glucose tolerance but only the combination therapy significantly reduced fasting blood glucose. Both treatments and their combination reduced leukocyte adhesion into the endothelium of brain venules. However, empagliflozin was more effective in preventing DM-induced microvascular rarefaction.Conclusion
These findings suggest that chronic treatment with SGLT2 inhibitors and GLP-1 receptor agonists may serve as potential therapeutic approaches to prevent microvascular complications associated with diabetes. 相似文献313.